Drug intelligence / Profile preview

axatilimab + retifanlimab + cyclophosphamide

Development stage: Unknown
Lead developer: Syndax Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

Axatilimab + retifanlimab + cyclophosphamide is an investigational chemo-immunotherapy combination regimen being evaluated for the treatment of metastatic triple-negative breast cancer (TNBC) and inflammatory breast cancer. The combination consists of axatilimab (SNDX-6352), a humanized monoclonal antibody that targets the colony-stimulating factor 1 receptor (CSF-1R) to deplete or reprogram immunosuppressive tumor-associated macrophages; retifanlimab (INCMGA00012), a humanized monoclonal antibody directed against the programmed death-1 (PD-1) receptor to enhance anti-tumor T-cell response; and low-dose oral cyclophosphamide, an alkylating agent used here for its potential immunomodulatory effects, such as depleting regulatory T cells. This approach, spearheaded by M.D. Anderson Cancer Center, aims to overcome immune resistance in aggressive breast cancer subtypes by simultaneously targeting multiple pathways within the tumor microenvironment.

Brand names: NiktimvoZynyzCytoxan
Other names: axatilimab-M.D. Anderson Cancer Center-triple negative breast cancer-inflammatory breast cancer

Targets

CSF1R (Macrophage colony-stimulating factor receptor)PDCD1 (Programmed cell death protein 1 receptor)DNA

Beyond the preview

Go deeper on axatilimab + retifanlimab + cyclophosphamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on axatilimab + retifanlimab + cyclophosphamide.

Explore the full profile